CAMBRIDGE, Mass. Sage Therapeutics (SAGE, Financials) announced a massive shakeup under its reorganization plan Thursday, led by a 33% reduction in its workforce, in supporting the launch of ZURZUVAE, its treatment for postpartum depression. Additionally, the reshuffling will enable the company to focus on advancing pipeline development before a key clinical readout for dalzanemdor, a drug candidate for Huntington's disease, that is slated to be released later this year.
The move, likely to offset over 165 employees, including 55% of its R&D staff, entails strengthening the company's balance sheet while extending its cash runway. The restructuring is set to be completed by Q4 2024.
Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich Schlieker, and Amy Schacterle. Chris Benecchi will be looking to take up the reins as Chief Operating Officer, overseeing several departments, while Greg Shiferman and Vanessa Procter will assume expanded leadership roles.
Sage's reorganization positions the company for the company's long-term expansion while managing costs and improving efficiency during ZURZUVAE's market introduction phase.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。